Retroelements in the human genome are silenced via multiple mechanisms, including DNA methylation, to prevent their potential mutagenic effect. Retroelement activity, demonstrated by their expression and somatic retrotransposition events, was shown to be deregulated in multiple tumors but not yet in leukemia. We hypothesized that treatment with hypomethylating agents, commonly used in myelodysplastic syndromes and acute myeloid leukemia, could lead to increased retroelement activity and somatic retrotranspositions, thus contributing to disease progression. To address this hypothesis, we induced the expression of ORF1p protein with hypomethylating agents in DAMI and HL-60 myeloid cell lines. To study whether long-term hypomethylating agent therapy induces somatic retrotranspositions, we analyzed (i) both cell lines treated for 4 weeks, and (ii) sequential samples from 17 patients with myelodysplastic syndrome treated with hypomethylating agents. Using a sensitive next-generation sequencing (NGS)-based method, no retroelement events were identified. To conclude, we show that although hypomethylating agents induce the expression of LINE-1-encoded proteins in myeloid cell lines, de novo somatic retrotransposition events do not arise during the long-term exposure to these agents.

Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Visceral Surgery University Hospital Rostock Germany

Institute of Medical Genetics and Genomics Faculty of Medicine Masaryk University Brno Czech Republic

Pirogov Russian National Research Medical University Moscow Russia

Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry Moscow Russia

Skolkovo Institute of Science and Technology Moscow Russia

Zobrazit více v PubMed

Wicker T, Sabot F, Hua‐Van A, Bennetzen JL, Capy P, Chalhoub B, et al. A unified classification system for eukaryotic transposable elements. Nat Rev Genet. 2007;8:973–982. PubMed

Brouha B, Schustak J, Badge RM, Lutz‐Prigge S, Farley AH, Moran JV, et al. Hot L1s account for the bulk of retrotransposition in the human population. Proc Natl Acad Sci USA. 2003;100:5280–5285. PubMed PMC

Streva VA, Jordan VE, Linker S, Hedges DJ, Batzer MA, Deininger PL. Sequencing, identification and mapping of primed L1 elements (SIMPLE) reveals significant variation in full length L1 elements between individuals. BMC Genomics. 2015;16:220. PubMed PMC

Taylor MS, LaCava J, Mita P, Molloy KR, Huang CR, Li D, et al. Affinity proteomics reveals human host factors implicated in discrete stages of LINE‐1 retrotransposition. Cell. 2013;155:1034–1048. PubMed PMC

Ardeljan D, Wang X, Oghbaie M, Taylor MS, Husband D, Deshpande V, et al. LINE‐1 ORF2p expression is nearly imperceptible in human cancers. Mob DNA. 2020;11:1. PubMed PMC

Mita P, Wudzinska A, Sun X, Andrade J, Nayak S, Kahler DJ, et al. LINE‐1 protein localization and functional dynamics during the cell cycle. eLife. 2018;7:e30058. PubMed PMC

Cost GJ, Feng Q, Jacquier A, Boeke JD. Human L1 element target‐primed reverse transcription in vitro. EMBO J. 2002;21:5899–5910. PubMed PMC

Doucet AJ, Wilusz JE, Miyoshi T, Liu Y, Moran JV. A 3′ poly(a) tract is required for LINE‐1 retrotransposition. Mol Cell. 2015;60:728–741. PubMed PMC

Ewing AD, Kazazian HH. High‐throughput sequencing reveals extensive variation in human‐specific L1 content in individual human genomes. Genome Res. 2010;20:1262–1270. PubMed PMC

Feusier J, Watkins WS, Thomas J, Farrell A, Witherspoon DJ, Baird L, et al. Pedigree‐based estimation of human mobile element retrotransposition rates. Genome Res. 2019;29:1567–1577. PubMed PMC

Rodić N, Sharma R, Zampella J, Dai L, Taylor MS, Hruban RH, et al. Long interspersed element‐1 protein expression is a hallmark of many human cancers. Am J Pathol. 2014;184:1280–1286. PubMed PMC

Ting DT, Lipson D, Paul S, Brannigan BW, Akhavanfard S, Coffman EJ, et al. Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science. 2011;331:593–596. PubMed PMC

Helman E, Lawrence MS, Stewart C, Sougnez C, Getz G, Meyerson M. Somatic retrotransposition in human cancer revealed by whole‐genome and exome sequencing. Genome Res. 2014;24:1053–1063. PubMed PMC

Lee E, Iskow R, Yang L, Gokcumen O, Haseley P, Luquette LJ, et al. Landscape of somatic retrotransposition in human cancers. Science. 2012;337:967–971. PubMed PMC

Rodriguez‐Martin B, Alvarez EG, Baez‐Ortega A, Zamora J, Supek F, Demeulemeester J, et al. Pan‐cancer analysis of whole genomes identifies driver rearrangements promoted by LINE‐1 retrotransposition. Nat Genet. 2020;52:306–319. PubMed PMC

Miki Y, Nishisho I, Horii A, Miyoshi Y, Utsunomiya J, Kinzler KW, et al. Disruption of the APC gene by a retrotransposal insertion of L1 sequence in a colon cancer. Cancer Res. 1992;52:643–645. PubMed

Rodríguez‐Martín C, Cidre F, Fernández‐Teijeiro A, Gómez‐Mariano G, de la Vega L, Ramos P, et al. Familial retinoblastoma due to intronic LINE‐1 insertion causes aberrant and noncanonical mRNA splicing of the RB1 gene. J Hum Genet. 2016;61:463–466. PubMed

Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, Siegmund KD, et al. Hypomethylation of a LINE‐1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. 2010;6:e1000917. PubMed PMC

Rauch TA, Zhong X, Wu X, Wang M, Kernstine KH, Wang Z, et al. High‐resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA. 2008;105:252–257. PubMed PMC

Sunami E, de Maat M, Vu A, Turner RR, Hoon DS. LINE‐1 hypomethylation during primary colon cancer progression. PLoS One. 2011;6:e18884. PubMed PMC

van Hoesel AQ, van de Velde CJ, Kuppen PJ, Liefers GJ, Putter H, Sato Y, et al. Hypomethylation of LINE‐1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study. Breast Cancer Res Treat. 2012;134:1103–1114. PubMed

Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, et al. DNA hypomethylation arises later in prostate cancer progression than CpG Island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008;68:8954–8967. PubMed PMC

Gao XD, Qu JH, Chang XJ, Lu YY, Bai WL, Wang H, et al. Hypomethylation of long interspersed nuclear element‐1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma. Liver Int. 2014;34:136–146. PubMed PMC

Pattamadilok J, Huapai N, Rattanatanyong P, Vasurattana A, Triratanachat S, Tresukosol D, et al. LINE‐1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:711–717. PubMed

Iwagami S, Baba Y, Watanabe M, Shigaki H, Miyake K, Ishimoto T, et al. LINE‐1 hypomethylation is associated with a poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. Ann Surg. 2013;257:449–455. PubMed

Urazbakhtin S, Smirnova A, Volakhava A, Zerkalenkova E, Salyutina M, Doubek M, et al. The absence of retroelement activity is characteristic for childhood acute leukemias and adult acute lymphoblastic leukemia. Int J Mol Sci. 2022;23:1756. PubMed PMC

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–629. PubMed

Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar‐Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440. PubMed

Komkov AY, Urazbakhtin SZ, Saliutina MV, Komech EA, Shelygin YA, Nugmanov GA, et al. SeqURE – a new copy‐capture based method for sequencing of unknown Retroposition events. Mob DNA. 2020;11:33. PubMed PMC

Nugmanov GA, Komkov AY, Saliutina MV, Minervina AA, Lebedev YB, Mamedov IZ. A pipeline for the error‐free identification of somatic Alu insertions in high‐throughput sequencing data. Mol Biol. 2019;53:154–165. PubMed

Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383:2239–2252. PubMed

Fenaux P, Haase D, Santini V, Sanz GF, Platzbecker U, Mey U, et al. Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2021;32:142–156. PubMed

Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113:1315–1325. PubMed PMC

Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010;28:605–613. PubMed PMC

Diesch J, Zwick A, Garz AK, Palau A, Buschbeck M, Götze KS. A clinical‐molecular update on azanucleoside‐based therapy for the treatment of hematologic cancers. Clin Epigenetics. 2016;8:71. PubMed PMC

Duchmann M, Itzykson R. Clinical update on hypomethylating agents. Int J Hematol. 2019;110:161–169. PubMed

Kurnosov AA, Ustyugova SV, Nazarov VI, Minervina AA, Komkov AY, Shugay M, et al. The evidence for increased L1 activity in the site of human adult brain neurogenesis. PLoS One. 2015;10:e0117854. PubMed PMC

Gu Z, Liu Y, Zhang Y, Cao H, Lyu J, Wang X, et al. Silencing of LINE‐1 retrotransposons is a selective dependency of myeloid leukemia. Nat Genet. 2021;53:672–682. PubMed PMC

Merkerova MD, Krejcik Z. Transposable elements and piwi‐interacting RNAs in hemato‐oncology with a focus on myelodysplastic syndrome (review). Int J Oncol. 2021;59:75. PubMed

Colombo AR, Zubair A, Thiagarajan D, Nuzhdin S, Triche TJ, Ramsingh G. Suppression of transposable elements in leukemic stem cells. Sci Rep. 2017;7:7029. PubMed PMC

Wylie A, Jones AE, D'Brot A, Lu WJ, Kurtz P, Moran JV, et al. p53 genes function to restrain mobile elements. Genes Dev. 2016;30:64–77. PubMed PMC

Levine AJ, Ting DT, Greenbaum BD. P53 and the defenses against genome instability caused by transposons and repetitive elements. Bioessays. 2016;38:508–513. PubMed PMC

Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–1228. PubMed PMC